Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippi applies for you, and finds you a job.
Atara Biotherapeutics's peak revenue was $128.9M in 2024. The peak quarterly revenue was $51.6M in 2022(q2).
Atara Biotherapeutics's revenue increased from $20.3m in 2021 to $128.9M currently. That's a 533.92% change in annual revenue.
| Fiscal year / year | Atara Biotherapeutics revenue |
|---|---|
| 2021 | $20.3M |
| 2022 | $63.6M |
| 2023 | $8.6M |
| 2024 | $128.9M |
Rate Atara Biotherapeutics' financial transparency
Atara Biotherapeutics saw the greatest revenue growth in 2022, when revenue increased by 212.55%.
Atara Biotherapeutics had the lowest revenue growth in 2022, when revenue changed by 212.55%.
| Year | Atara Biotherapeutics growth |
|---|---|
| 2022 | 213%↑ |
| 2023 | -87%↓ |
| 2024 | 1404%↑ |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2021 | $3.6M | $3.9M | $5.4M | $7.5M |
| 2022 | $7.3M | $51.6M | $4.5M | $221,000 |
| 2023 | $1.2M | $957,000 | $2.1M | $4.3M |
| 2024 | $27.4M | $28.6M | $40.2M | $32.8M |
Do you work at Atara Biotherapeutics?
Did Atara Biotherapeutics meet its revenue projections?
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 578 |
| Date Founded | 2012 |
| Headquarters | South San Francisco, California |
| Number of Locations | 6 |
| Revenue | $128.9M |
| Net Income | -$228,302,000 |
| Gross Proft | $107.9M (2024) |
| PE Ratio | -5.43 |
| Tax Rate | 0.0% |
| Market Capitalization | $463.7M |
| Total Assets | $376,420,000 |
| Ticker | ATRA |
Atara Biotherapeutics received early financing of $1.0M on 2013-03-31.
| Series | Round size | Date |
|---|---|---|
| Series Unknown | $1M | 03/2013 |
| Series B | $38.5M | 12/2013 |
| Series B | $13.5M | 01/2014 |
| Series Unknown | $6.3M | 01/2014 |
| Investors | Security type |
|---|---|
| Domain Associates | Series Unknown |
| Alexandria Venture | Series B |
| EcoR1 Capital LLC | Series B |
| CELGENE CORP DE | Series B |
| DAG Ventures | Series B |
| Kleiner Perkins | Series B |
| Amgen Inc. | Series B |
| Domain Associates | Series B |
| Alexandria Venture | Series B |
| EcoR1 Capital LLC | Series B |
| CELGENE CORP DE | Series B |
| DAG Ventures | Series B |
| Kleiner Perkins | Series B |
| Amgen Inc. | Series B |
| Domain Associates | Series B |
Zippia gives an in-depth look into the details of Atara Biotherapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Atara Biotherapeutics. The employee data is based on information from people who have self-reported their past or current employments at Atara Biotherapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Atara Biotherapeutics. The data presented on this page does not represent the view of Atara Biotherapeutics and its employees or that of Zippia.
Atara Biotherapeutics may also be known as or be related to ATARA BIOTHERAPEUTICS INC., Atara Biotherapeutics, Atara Biotherapeutics Inc and Atara Biotherapeutics, Inc.